EGFR and glioma: Rindopepimut (also known as CDX-110), a vaccine targeting the epidermal growth factor receptor (EGFR) deletion mutation EGFRvIII, has received drug approval from the US FDA for the breakthrough treatment of EGFRvIII-positive gliomas in adult patients (23).